<VariationArchive RecordType="classified" VariationID="456446" VariationName="NC_000001.10:g.(?_100366308)_(100367832_?)del" VariationType="Deletion" Accession="VCV000456446" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2017-12-26" MostRecentSubmission="2017-12-26">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="446966" VariationID="456446">
      <GeneList>
        <Gene Symbol="AGL" FullName="amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase" GeneID="178" HGNC_ID="HGNC:321" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p21.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="99849258" stop="99924023" display_start="99849258" display_stop="99924023" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="100315639" stop="100389578" display_start="100315639" display_stop="100389578" Strand="+" />
          </Location>
          <OMIM>610860</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000001.10:g.(?_100366308)_(100367832_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p21.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" innerStart="100366308" innerStop="100367832" display_start="100366308" display_stop="100367832" variantLength="1525" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.(?_100366308)_(100367832_?)del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.(?_100366308)_(100367832_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000001.10:g.(?_100366308)_(100367832_?)del AND Glycogen storage disease type III" Accession="RCV000544604" Version="1">
        <ClassifiedConditionList TraitSetID="6278">
          <ClassifiedCondition DB="MedGen" ID="C0017922">Glycogen storage disease type III</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-02-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2017-02-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-12-26" MostRecentSubmission="2017-12-26">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="6278" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2236" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Forbes disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cori disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Limit dextrinosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Amylo-1,6-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen debrancher deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Glycogen storage disease type III</ElementValue>
                <XRef ID="Glycogen+Storage+Disease+Type+3/3123" DB="Genetic Alliance" />
                <XRef ID="66937008" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GSD3</ElementValue>
                <XRef Type="MIM" ID="232400" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9442" />
                <XRef ID="9442" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Glycogen storage disease type III (GSD III) is characterized by variable liver, cardiac muscle, and skeletal muscle involvement. GSD IIIa is the most common subtype, present in about 85% of affected individuals; it manifests with liver and muscle involvement. GSD IIIb, with liver involvement only, comprises about 15% of all affected individuals. In infancy and early childhood, liver involvement presents as hepatomegaly and failure to thrive, with fasting ketotic hypoglycemia, hyperlipidemia, and elevated hepatic transaminases. In adolescence and adulthood, liver disease becomes less prominent. Most individuals develop cardiac involvement with cardiac hypertrophy and/or cardiomyopathy. Skeletal myopathy manifesting as weakness may be evident in childhood and slowly progresses, typically becoming prominent in the third to fourth decade. The overall prognosis is favorable but cannot be predicted on an individual basis. Long-term complications such as muscular and cardiac symptoms as well as liver fibrosis/cirrhosis and hepatocellular carcinoma may have a severe impact on prognosis and quality of life. To date, it is unknown if long-term complications can be alleviated and/or avoided by dietary interventions.</Attribute>
                <XRef ID="NBK26372" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301788</ID>
                <ID Source="BookShelf">NBK26372</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, 2010">
                <ID Source="PubMed">20631546</ID>
              </Citation>
              <XRef ID="366" DB="Orphanet" />
              <XRef ID="C0017922" DB="MedGen" />
              <XRef ID="MONDO:0009291" DB="MONDO" />
              <XRef Type="MIM" ID="232400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1218851" SubmissionDate="2017-10-05" DateLastUpdated="2017-12-26" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1467408|MedGen:C0017922" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000626658" DateUpdated="2017-12-26" DateCreated="2017-12-26" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-02-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">This variant is a deletion of the genomic region encompassing the last 110 nucleotides of exon 26 and most of intron 26 of the AGL gene (c.3479_3589-407del). This creates a premature translational stop signal and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in AGL are known to be pathogenic (PMID: 26984562, 27106217). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="AGL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.(?_100366308)_(100367832_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017922" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3109251</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1218851" TraitType="Disease" MappingType="XRef" MappingValue="C0017922" MappingRef="MedGen">
        <MedGen CUI="C0017922" Name="Glycogen storage disease type III" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

